drugset

drugset / Trial / NCT01867879

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

NCT01867879 ↗

Phase 1 Completed 44 enrolled Taiho Oncology, Inc.

Non-randomizedSingle-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the cardiac safety of TAS-102 in patients with advanced solid tumors.

Timeline

Start: 2013-06
Primary completion: 2014-08
Completion: 2015-04

Publications

Bendell JC, Patel MR, Yoshida K, Seraj J, Weaver R, Lemech C, Todaro TG, Pant S, Arkenau HT. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Jun;77(6):1275-83. doi: 10.1007/s00280-016-3031-9. Epub 2016 May 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TAS-102	Small molecule	35 mg/m2	Oral

Indications

No indication recorded.